Alzheimer’s, ok for the sale of the first in vitro test for early diagnosis

It can be purchased, then used to understand if there is a predisposition to Alzheimer’s. It is the first in vitro diagnostic test for the early diagnosis of amyloid plaques associated with the disease, which the US Food and Drug Administration has authorized for commercialization. It is called Lumipulse G β-Amiloid Ratio (1-42 / 1-40), and is intended for use in adult patients, 55 years of age and older, who have cognitive impairment who are being evaluated for Alzheimer’s and other causes of cognitive decline.